MedDataX Logo

Characteristics of COVID-19 Patients in Kazakhstan in Early 2020

NCT ID: NCT04627194

Last Updated: 2020-11-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

1000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-02-20

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to assess the epidemiological and clinical features of patients diagnosed with COVID-19 in Kazakhstan at the onset of the pandemic.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

There is a paucity of data available on the epidemiological and clinical characteristics of coronavirus disease 2019 (COVID-19) in Kazakhstan. While a global effort in search for effective treatments and vaccines against COVID-19 is in effect, it is important that high quality and up-to-date information be available from a broad variety of populations on the dynamics of infection. This is especially important in regions where, due to resource shortage, epidemiologic surveillance may have gaps. To address the current gaps, medical records will be obtained for patients with confirmed COVID-19 during the first months of the pandemic (February-April 2020). The epidemiologic and clinical features including the demographics, clinical manifestation, laboratory parameters, radiologic assessments and clinical outcomes will be analyzed. The results of this study will facilitate the clinical management of COVID-19 patients in Kazakhstan and ultimately inform the ongoing efforts to curb the spread of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the region.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19 Pneumonia, Viral

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Mild and asymptomatic COVID-19 patients

Symptomatic patients meeting the World Health Organization (WHO) case definition for COVID-19 without evidence of viral pneumonia or hypoxia, who have a laboratory-confirmed SARS-CoV-2 infection, or asymptomatic patients with a laboratory-confirmed SARS-CoV-2 infection at the time of hospitalization.

No interventions assigned to this group

Moderate severity COVID-19 patients

Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition for moderate COVID-19 disease severity \[including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, but no signs of severe pneumonia\] at the time of hospitalization.

No interventions assigned to this group

Severe-to-critical COVID-19 patients

Symptomatic patients with a laboratory-confirmed SARS-CoV-2 infection, meeting the WHO case definition(s) for severe COVID-19 disease presentation \[including clinical signs of pneumonia e.g. fever, cough, dyspnoea, fast breathing, and one of the following: respiratory rate \> 30 breaths/min; severe respiratory distress; or oxygen saturation (SpO2) \< 90% on room air\] or for critical COVID-19 disease presentation \[including acute respiratory distress syndrome (ARDS), sepsis, septic shock or other complications such as acute pulmonary embolism, acute coronary syndrome, acute stroke and delirium\] at the time of hospitalization.

No interventions assigned to this group

COVID-19 survivors

Patients diagnosed with a laboratory-confirmed COVID-19, who survived.

No interventions assigned to this group

COVID-19 non-survivors

Patients diagnosed with a laboratory-confirmed COVID-19, who did not survive.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Laboratory confirmation of SARS-CoV-2 infection by polymerase chain reaction.
Minimum Eligible Age

0 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Semey State Medical University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Yersin Zhunussov, MD, D.M.S.

Role: STUDY_CHAIR

Semey State Medical University

Raifa Ivanova, MD, D.M.S.

Role: STUDY_DIRECTOR

Semey State Medical University

Maiya Goremykina, M.D, C.M.S

Role: PRINCIPAL_INVESTIGATOR

Semey State Medical University

Sergey Yegorov, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Nazarbayev University, School of Sciences and Humanities

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Semey Medical University

Semey, East Kazakhstan, Kazakhstan

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kazakhstan

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

76.29.31_48.04.06-01

Identifier Type: -

Identifier Source: org_study_id